The company said yesterday that a phase 3 trial in ovarian cancer patients showed that patupilone was unable to increase survival compared to Johnson & Johnson's
It is possible that patupilone actually works as well as Doxil/Caelyx, but not better than it. Novartis' exact quote was that the drug "did not show a significant overall survival advantage." Until the company releases the full data set, investors can hold out hope that the drug works, just not enough to justify bringing it to market for ovarian cancer patients.
Novartis is also testing patupilone against other cancers, including metastatic colorectal cancer, metastatic lung cancer, and prostate cancer, and I wouldn't discount its chances of success based on this one trial.
First, there are many examples of cancer drugs working for one tumor type but not another. Pfizer's
Second, the patients in this trial were pretty sick. They could have failed up to three previous chemotherapy regimens, including one of the standard first-line treatments of Bristol-Myers Squibb's
It looks like patupilone went wide of goal this time; fortunately Novartis still has a few more shots.
Matt Hoffman explains how soccer is like investing without using shots on goal metaphors.
Novartis is a Motley Fool Global Gains selection. Investing internationally doesn't have to be scary and it can certainly be profitable. Click here to grab a 30-day trial subscription to the newsletter where you'll see all of our current picks for a global economy.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a recommendation of the Inside Value newsletter. Johnson & Johnson is an Income Investor selection and Motley Fool Options recommended buying calls on the stock. The Fool has a disclosure policy.